Continuous Glucose Monitoring (CGM) has become a important technology in the management and research of both type 1 and type 2 diabetes, providing real-time data on glucose fluctuations that were previously inaccessible with traditional monitoring methods. Numerous analytical tools, such as cgmquantify, iglu, GLU, rGV, and CGManalyzer, have been developed for platforms like R and Python to calculate standard metrics and extract insights from CGM data. However, these tools often fail to address the full spectrum of analytical requirements. Furthermore, there is a significant lack of updated, open-source tools tailored for MATLAB, a platform widely used by the research community. To address this gap, we introduce Quantification of Continuous Glucose Monitoring (QoCGM), a comprehensive, open-source analytical tool for CGM data specifically designed for MATLAB. A case study involving 324 individuals with insulin-treated type 2 diabetes mellitus (T2DM) demonstrates the utility of QoCGM, highlighting the distinct aspects of glucose dynamics captured by different CGM derived metrics through an analysis of their coefficients of determination (R^2).

SLC received funding from i-SENS, Inc (Seoul, South Korea) and SLCs involvement with the company did not influence the design, implementation, or interpretation of the study. The study was conducted independently, and the authors declare that their involvement with i-SENS, Inc (Seoul, South Korea) did not influence the findings or conclusions of the study. MHJ has received consultant feed from Abbott.

the study on the QoCGM development was funded by i-SENS, Inc (Seoul, South Korea).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Diabetes teleMonitoring of patients in insulin Therapy (DiaMonT) was approved by the Regional Ethical Committee of North Jutland, Denmark (N-20200068)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The data utilized in this study are not publicly available due to the inclusion of sensitive patient information, which is subject to strict confidentiality and privacy regulations. Access to the data is restricted to ensure compliance with ethical guidelines and to protect patient privacy. Requests for additional information or collaboration may be considered on a case-by-case basis, subject to appropriate ethical approval and data-sharing agreements.